Orleans, France

Lucile Mollet

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Location History:

  • Paris, FR (2015)
  • Orleans, FR (2018 - 2020)

Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Lucile Mollet: Innovator in Vaccine Development

Introduction

Lucile Mollet is a prominent inventor based in Orleans, France. She has made significant contributions to the field of vaccine development, particularly through her innovative work with recombinant measles viruses. With a total of 5 patents, her research has the potential to impact public health positively.

Latest Patents

One of her latest patents is titled "Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions." This invention relates to a recombinant measles virus that expresses a heterologous amino acid sequence derived from an antigen of a specific RNA virus. The recombinant measles virus is capable of eliciting a humoral and/or cellular immune response against both the measles virus and the RNA virus. Additionally, it pertains to the use of this recombinant measles virus for the preparation of immunogenic compositions.

Career Highlights

Lucile Mollet has worked with esteemed organizations such as the Centre National de la Recherche Scientifique and Institut Pasteur. Her work in these institutions has allowed her to advance her research and contribute to the scientific community significantly.

Collaborations

Some of her notable coworkers include Clarisse Lorin and Frederic Tangy. Their collaboration has likely enriched her research endeavors and fostered innovation in the field.

Conclusion

Lucile Mollet's contributions to vaccine development through her innovative patents and collaborations highlight her importance in the scientific community. Her work continues to pave the way for advancements in immunology and public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…